Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Aflibercept Monotherapy With Early DCE-Ultrasound Monitoring in Chemorefractory Metastatic Colorectal Cancer
2014-002003-25Phase 2Terminated
- Sponsor
- Barts Health NHS Trust
- Start
- Aug 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aflibercept in metastatic colon cancer (mCRC), sponsored by Barts Health NHS Trust. Primary endpoint: Overall survival by DCE-US vascular shutdown status. Started Aug 2017; status: terminated.
02
Drugs
aflibercept
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2014-002003-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002003-25.